Fourth quarter 2010 R&D expenses decreased to $23.6m from $31.6m in last year, driven by lower development costs associated with the peramivir and forodesine clinical programs.
Total revenues of $17.8m consisted primarily of reimbursement of collaboration expenses, including $14.9m from the contract with the Department of Health and Human Services (HHS) for the continued development of iv peramivir and the recognition of $1.1m in grant income from the US Government’s Qualifying Therapeutic Discovery Project (QTDP) program.
For the full year ended 31 December 2010, net loss was $32.7m, compared to a net loss of $13.5m for the same period in 2009.
Full year 2010 total revenues decreased to $63.5m from $74.6m in 2009.
In addition, BioCryst recognized less revenue from its collaboration with Mundipharma during 2010 compared to 2009.